Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Melody Smith(Memorial Sloan Kettering Cancer Center), Marco Ruella(Parker Institute for Cancer Immunotherapy), Jakub Svoboda(UPMC Hillman Cancer Center), Anqi Dai(Memorial Sloan Kettering Cancer Center), Jonas Schlüter(Hinge Health), Justin R. Cross(Memorial Sloan Kettering Cancer Center), Annelie Clurman(Cornell University), Carl H. June(University of Pennsylvania), Eric R. Littmann, Antonio L. C. Gomes(Cornell University), Shannon Gier(University of Pennsylvania), Elise A. Chong(Hospital of the University of Pennsylvania), Eric G. Pamer(University of Illinois Chicago), Pamela S. Herrera(Memorial Sloan Kettering Cancer Center), Ying Taur(Memorial Sloan Kettering Cancer Center), Aishat Olaide Afuye(Memorial Sloan Kettering Cancer Center), Jonathan U. Peled(Memorial Sloan Kettering Cancer Center), Alfred L. Garfall(University of Pennsylvania), Isabelle Rivière(Memorial Sloan Kettering Cancer Center), Guido Ghilardi(Hospital of the University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), James N. Gerson(UPMC Hillman Cancer Center), Kimberly V. Amelsberg(Hospital of the University of Pennsylvania), Daniel J. Landsburg(University of Pennsylvania), Gabriel K. Armijo(Cornell University), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), David L. Porter(Chapman University), Craig W. Freyer(Hospital of the University of Pennsylvania), Tania Jain(Johns Hopkins University), Paul A. Giardina(Memorial Sloan Kettering Cancer Center), Michel Sadelain(Columbia University Irving Medical Center), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center), Emily Fontana(Cornell University), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Elizabeth Halton(Memorial Sloan Kettering Cancer Center), Stephen J. Schuster(Hospital of the University of Pennsylvania), Andrea Facciabene(Hospital of the University of Pennsylvania), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Silvia Beghi(Hospital of the University of Pennsylvania), Raymone Pajarillo(Hospital of the University of Pennsylvania), Sunita D. Nasta(University of Pennsylvania), John Slingerland(Cornell University), Noelle V. Frey(Hospital of the University of Pennsylvania), Jae H. Park(Memorial Sloan Kettering Cancer Center), Josel D. Ruiz, Emmanuel Agyemang Dwomoh(Memorial Sloan Kettering Cancer Center), Martina Pennisi(University of Milan), Maria Lia Palomba(Memorial Sloan Kettering Cancer Center), Marcel R.M. van den Brink(City Of Hope National Medical Center)
Cited by 308
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
|Nature Reviews Clinical Oncology|2019|1.4k